Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Incidence of R/R DLBCL Lower Than Expected in Population-Based Study

Key clinical point: The 5-year cumulative incidence of primary refractory disease and relapse (R/R) in patients with diffuse large B-cell lymphoma (DLBCL) who were treated with curative intent was lower than in previously published reports.

Major finding: The 5-year cumulative incidence of primary refractory disease and relapse in a population-based setting was 21%. The 2-year cumulative incidence of CNS progression/relapse when accounting for competing risks was low at 2.9%.

Study details: A population-based study of 4,202 patients with a primary diagnosis of DLBCL in 2007-2014 and followed until October 31, 2017.

Disclosures: The study was funded by the Karolinska Institutet and Janssen Pharmaceuticals as well as the Swedish Cancer Society.

Citation:

Harrysson S et al. ASH 2019. Abstract 399.